Primary hepatic leiomyosarcoma is exceedingly rare accounting for less than 1% of the hepatic tumors. Close to 45 cases have been reported in the English literature. Presentation is usually nonspecific and diagnosis is often delayed until tumors reach a large size. This leads to a dismal prognosis. The tumors are not yet fully understood, hence the standard of care is not well defined. Curative resection remains the mainstay of management. Close association of Epstein Barr virus (EBV) induced soft tissue sarcomas is proven, especially in the presence of immunosuppression encountered in HIV/AIDS patients and in posttransplant patients. We herein present a case report of a 54-year-old man diagnosed to have HIV/AIDS and EBV infection admitted to our hospital with complaints of intractable hiccups for more than a week. Extensive workup revealed primary leiomyosarcoma of the liver. 1. Introduction Sarcomas are rare mesenchymal tumors and account for 1% of all adult tumors, of which 5–10% are leiomyosarcomas. Hepatic leiomyosarcomas are unusual tumors. Most of them are metastatic leiomyosarcomas. Primary hepatic leiomyosarcoma is a very rare entity. Primary leiomyosarcomas are known to occur in uterus, retroperitoneum, genital organs, major blood vessels of the body, lungs, and liver [1]. They usually present with nonspecific symptoms and the diagnosis is often delayed resulting in poor prognosis. We herein present a case of a 54- year- old man with HIV/AIDS and EBV infection presenting with intractable hiccups and subsequent workup led to the diagnosis of primary hepatic leiomyosarcoma. 2. Case Report A 54- year- old African American man presented to our hospital with intractable hiccups that started about a week prior to admission. He also reported intermittent low grade fever with poor oral intake and weight loss of 9 kilograms for the last 3 months. He denied abdominal pain, nausea, vomiting, or irregular bowel habits. His comorbidities included HIV/AIDS, seizure disorder, and hypertension. His CD4 count was 24 at the time of admission. He had no history of liver disease or alcohol abuse. He never had any surgery. Family history was negative for any malignancies or liver disease. On physical examination he appeared cachectic. He had no palpable lymph nodes. Abdominal examination revealed minimal tenderness in the right upper quadrant and hepatomegaly of about 6?cm below the right costal margin. Laboratory analysis revealed alanine aminotransferase 81?IU/L (0–34?IU/L), aspartate aminotransferase 56?IU/L (0–40?IU/L), alkaline phosphatase 160?IU/L
References
[1]
U. Cioffi, P. Quattrone, M. De Simone et al., “Primary multiple epithelioid leiomyosarcoma of the liver,” Hepato-Gastroenterology, vol. 43, no. 12, pp. 1603–1605, 1996.
[2]
P. Gustafson, H. Willén, B. Baldetorp, M. Fern?, M. Akerman, and A. Rydholm, “Soft tissue leiomyosarcoma. A population-based epidemiologic and prognostic study of 48 patients, including cellular DNA content,” Cancer, vol. 70, no. 1, pp. 114–149, 1992.
[3]
H. S. Maki, B. C. Hubert, S. M. Sajjad, J. P. Kirchner, and M. E. Kuehner, “Primary hepatic leiomyosarcoma,” Archives of Surgery, vol. 122, no. 10, pp. 1193–1196, 1987.
[4]
J. Weitz, D. S. Klimstra, K. Cymes et al., “Management of primary liver sarcomas,” Cancer, vol. 109, no. 7, pp. 1391–1396, 2007.
[5]
G. Civardi, L. Cavanna, E. Iovine, E. Buscarini, D. Valus A, and L. Buscarin, “Diagnostic imaging of primary hepatic leiomyosarcoma: a case report,” Italian Journal of Gastroenterology, vol. 28, no. 2, pp. 98–101, 1996.
[6]
H. Holloway, C. B. Walsh, R. Thomas, and J. Fielding, “Primary hepatic leiomyosarcoma,” Journal of Clinical Gastroenterology, vol. 23, no. 2, pp. 131–133, 1996.
[7]
M. Chi, A. Z. Dudek, and K. P. Wind, “Primary hepatic leiomyosarcoma in adults: analysis of prognostic factors,” Onkologie, vol. 35, no. 4, pp. 210–214, 2012.
[8]
F. Ferrozzi, D. Bova, A. Zangrandi, and G. Garlaschi, “Primary liver leiomyosarcoma: CT appearance,” Abdominal Imaging, vol. 21, no. 2, pp. 157–160, 1996.
[9]
P. Soyer, D. A. Bluemke, M. Riopel, R. H. Hruban, and E. K. Fishman, “Hepatic leiomyosarcomas: CT features with pathologic correlation,” European Journal of Radiology, vol. 19, no. 3, pp. 177–182, 1995.
[10]
H. Fujita, M. Kiriyama, T. Kawamura et al., “Primary hepatic leiomyosarcoma in a woman after renal transplantation: report of a case,” Surgery Today, vol. 32, no. 5, pp. 446–449, 2002.
[11]
K. Ohtomo, T. Araki, Y. Itai et al., “MR imaging of malignant mesenchymal tumors of the liver,” Gastrointestinal Radiology, vol. 17, no. 1, pp. 58–62, 1992.
[12]
P. Soyer, F. Blanc, C. Vissuzaine, J.-P. Marmuse, and Y. Menu, “Primary leiomyosarcoma of the liver: MR findings,” Clinical Imaging, vol. 20, no. 4, pp. 273–275, 1996.
[13]
M. B. Smith, J. F. Silverman, S. S. Raab, B. D. Towell, and K. R. Geisinger, “Fine-needle aspiration cytology of hepatic leiomyosarcoma,” Diagnostic Cytopathology, vol. 11, no. 4, pp. 321–327, 1994.
[14]
T. Higuchi, M. Kikuchi, and Y. Yamada, “Rapidly growing hepatic leiomyosarcoma: an immunohistochemical evaluation of malignant potential with monoclonal antibody MIB-1,” American Journal of Gastroenterology, vol. 89, no. 11, pp. 2098–2099, 1994.
[15]
S. Sprog?e-Jakobsen and B. H?lund, “Immunohistochemistry (Ki-67 and p53) as a tool in determining malignancy in smooth muscle neoplasms (exemplified by a myxoid leiomyosarcoma of the uterus),” APMIS, vol. 104, no. 10, pp. 705–708, 1996.
[16]
J. L. Poggio, D. M. Nagorney, A. G. Nascimento et al., “Surgical treatment of adult primary hepatic sarcoma,” British Journal of Surgery, vol. 87, no. 11, pp. 1500–1505, 2000.
[17]
J. Weitz, D. S. Klimstra, K. Cymes et al., “Management of primary liver sarcomas,” Cancer, vol. 109, no. 7, pp. 1391–1396, 2007.
[18]
M. E. King, G. R. Dickersin, and R. E. Scully, “Myxoid leiomyosarcoma of the uterus. A report of six cases,” American Journal of Surgical Pathology, vol. 6, no. 7, pp. 589–598, 1982.
[19]
J. F. Tierney, L. A. Steward, and M. K. B. Parmar, “Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data,” The Lancet, vol. 350, no. 9092, pp. 1647–1654, 1997.
[20]
D. K. Rajan, M. C. Soulen, T. W. I. Clark et al., “Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization,” Journal of Vascular and Interventional Radiology, vol. 12, no. 2, pp. 187–193, 2001.
[21]
T. L. Husted, G. Neff, M. J. Thomas, T. G. Gross, E. S. Woodle, and J. F. Buell, “Liver transplantation for primary or metastatic sarcoma to the liver,” American Journal of Transplantation, vol. 6, no. 2, pp. 392–397, 2006.
[22]
A. Rajput and W. G. Kraybill, “Clinical trials and soft tissue sarcomas,” Surgical Oncology Clinics of North America, vol. 12, no. 2, pp. 485–497, 2003.
[23]
B. Brichard, F. Smets, E. Sokal et al., “Unusual evolution of an Epstein-Barr virus-associated leiomyosarcoma occurring after liver transplantation,” Pediatric Transplantation, vol. 5, no. 5, pp. 365–369, 2001.